Arrow-right Camera
The Spokesman-Review Newspaper

The Spokesman-Review Newspaper The Spokesman-Review

Spokane, Washington  Est. May 19, 1883
Cloudy 27° Cloudy
News >  Nation

Oklahoma reaches $8.75 million settlement with opiate maker

Oklahoma Attorney General Mike Hunter talks with reporters in Norman, Okla., on Oct. 15, 2019. The state of Oklahoma will receive $8.75 million from two pharmaceutical companies as part of a deal that will end legal action the state was considering against the opioid manufacturers. (Sue Ogrocki / AP)
Oklahoma Attorney General Mike Hunter talks with reporters in Norman, Okla., on Oct. 15, 2019. The state of Oklahoma will receive $8.75 million from two pharmaceutical companies as part of a deal that will end legal action the state was considering against the opioid manufacturers. (Sue Ogrocki / AP)
Associated Press

OKLAHOMA CITY – The state of Oklahoma will receive $8.75 million from two pharmaceutical companies in a deal announced Friday that will end legal action the state was considering against the opioid manufacturers.

Oklahoma Attorney General Mike Hunter announced the agreement with Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc., both subsidiaries of Dublin-based Endo International. Without the agreement, Hunter said he planned to file suit against the company alleging it violated state law by deceptively marketing opioid pain medications in a way that understated the risk of addiction.

The company denied the allegations and admitted no wrongdoing as part of the agreement.

Endo’s Executive Vice President Matthew Maletta said in a statement that the company was pleased with the resolution.

Endo in 2016 withdrew the pain medication it produced, Opana and Opana ER, from the market and discontinued research and development into opiate drugs, Hunter said.

“The measures taken by Endo to alleviate the opioid epidemic are commendable,” Hunter said in a statement.

After a trial last summer, an Oklahoma judge ordered drugmaker Johnson & Johnson to pay the state $465 million to address the state’s opioid crisis. The state also reached pre-trial settlements totaling $355 million with two other drugmakers: Oxycontin-maker Purdue Pharma and Israeli-owned Teva Pharmaceuticals.

The Spokesman-Review Newspaper

Local journalism is essential.

Give directly to The Spokesman-Review's Northwest Passages community forums series -- which helps to offset the costs of several reporter and editor positions at the newspaper -- by using the easy options below. Gifts processed in this system are not tax deductible, but are predominately used to help meet the local financial requirements needed to receive national matching-grant funds.

Active Person

Subscribe to the Coronavirus newsletter

Get the day’s latest Coronavirus news delivered to your inbox by subscribing to our newsletter.